Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients with Type 2 Diabetes

Exclusion Criteria

• - Have type 1 diabetes or known latent autoimmune diabetes in adults
• - Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks prior to study start
• - Are receiving treatment for gastrointestinal disease with a drug directly affecting gastrointestinal motility (e.g., metoclopramide, cisapride, and chronic macrolide antibiotics)
• - Have used any prescription drug to promote weight loss within 3 months prior to study start
• - Have received treatment within 30 days prior to study start with a drug that has not received regulatory approval for any indication at the time of study entry
• - Have previously completed or withdrawn from this study or any other study investigating exenatide or GLP-1 analogs